Nutra Pharma Corp (NPHC) Total Liabilities (2010 - 2026)

Nutra Pharma has disclosed Total Liabilities across 17 years of filings, most recently posting $21.8 million for Q2 2026.

• In Q2 2026, Total Liabilities rose 30.79% year-over-year to $21.8 million; the TTM figure through Jun 2026 stood at $21.8 million (up 30.79% YoY), while the FY2025 annual figure was $17.4 million, up 13.24% from the prior year.
• Total Liabilities came in at $21.8 million for Q2 2026 at Nutra Pharma, up from $17.9 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $21.8 million in Q2 2026 to a low of $13.1 million in Q4 2022.
• Average Total Liabilities over 5 years is $16.0 million, with a median of $15.9 million recorded in 2022.
• Year-over-year, Total Liabilities plunged 61.77% in 2022 and soared 30.79% in 2026.
• Over 5 years, Total Liabilities stood at $13.1 million in 2022, then increased by 9.72% to $14.4 million in 2023, then gained by 6.93% to $15.4 million in 2024, then gained by 13.24% to $17.4 million in 2025, then grew by 25.12% to $21.8 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $21.8 million in Q2 2026, $17.9 million in Q1 2026, and $17.4 million in Q4 2025.